Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
07 Dec 2017 Social Prospective study of 133 IBD pts (64% CD, 36% UC) switched from Remicade to biosimilar Inflectra. After 12 mos. no differences in drug levels, disease activity between innovator and biosimilar. https://t.co/QEH3lUaXD4
22 Nov 2016 Social RT @DrPetryna: Sarilumab (IL6R) superior to Humira in MONARCH phase 3 trial. neutropenia &abn LFT > with sarilumab https://t.co/2Rwxz8hiZQ…
03 Oct 2018 Social RT @RheumNow: Often Not discussed but do you combine Otezla with a biologic (TNFi or IL-17 inhibitor) in your difficult PsA patients? Rheum…
15 Mar 2016 Social 63 Actemra nonresponders switched to TNFi (41) or Orencia (22) - more TNFi achieved LDAS (CDAI<10) (64% vs 24% ABA) https://t.co/xmAuMJN4Gd
30 Apr 2015 Social Negative RCT of RTX vs PBO in pts w/ ITP (PLT<30k) on background steroids. No difference in response or relapse rates http://buff.ly/1HHoCni 
29 Jan 2017 Social CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/OlN3Eyqya4
12 Jan 2017 Social Biosimilar Inflectra priced at only a 15% discount; CMS issues paymentand claims processing information https://t.co/lCwn198PAN
05 Nov 2018 Social Oct 31st Sandoz announced that the FDA has approved its adalimumab biosimilar named Hyrimoz (adalimumab-adaz) with indications for RA, JIA, PsA, AS, Crohns, ulcerative colitis and plaque psoriasis. https://t.co/9gH3X51GQj
05 May 2016 Social There is insufficient evidence that platelet rich plasma treatment benefits patellar tendinopathy. https://t.co/MIgQPx9kZR
19 Aug 2017 Social RheumNow Wk in Review up! How to store enbrel, over/under testing. Check out podcast https://t.co/I5b8tFK7Oa video https://t.co/rJ2nMY6woD
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb
13 Nov 2019 Social RT @EBRheum: Great talk by Dr. Manzi for Year in Review! See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NO…
23 Jun 2016 Social 47 RA/Psoriasis women exposed to Tofacitinib: 25 healthy, 1 congen. pulm stenosis 7 spont abortions. 8 terminations…/buff.ly/28MhtFh
17 Feb 2017 Social ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos https://t.co/hb6RdEnWj6
24 May 2018 Social Sandoz announces the approval of its infliximab biosimilarZessly (infliximab) by the European Commission. It is approved for use in RA, , adult & pediatric Crohn’s, adult & pediatric ulcerative colitis, AS, PsA and plaque psoriasis https://t.co/V0PJHbeLSp
10 Jun 2016 Social BMS Orencia data presented @ #EULAR16; including #CORRONA data showing RF+ or CCP+ assoc w/ better Orencia responses https://t.co/EHiE9G7x7N
13 Sep 2017 Social Sandoz announces FDA will review its biosimilar version of rituximab https://t.co/80E1jopxqd
06 Jul 2015 Social Pfizer has submitted to the FDA (for review) a new once-a-day Xeljanz (tofacitinib) 11 mg qd (equal to 5 mg bid) http://t.co/a3HI2akJEr
23 Aug 2016 Social Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra) https://t.co/T28ggiTGyA
07 Apr 2017 Social Dr. Laura Cappelli - Talk on checkpoint inhibitors of PD-1 (nivolumab, pembrolizumab) and CTLA4 (impilimumab) commonly used in chemotherapy